Immunization with an HPV-16 L1-based chimeric virus-like particle containing HPV-16 E6 and E7 epitopes elicits long-lasting prophylactic and therapeutic efficacy in an HPV-16 tumor mice model

Annual Report to the Nation on the Status of Cancer, 1975–2009, Featuring the Burden and Trends in Human Papillomavirus (HPV)–Associated Cancers and HPV Vaccination Coverage Levels

(2013) Ahmedin Jemal et al.   JNCI-Journal of the National Cancer Institute

TriVax-HPV: an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers

(2012) Kelly Barrios et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Human papillomavirus 16 L1–E7 chimeric virus like particles show prophylactic and therapeutic efficacy in murine model of cervical cancer

(2012) Chandresh Sharma et al.   VACCINE

A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines

(2012) John T. Schiller et al.   VACCINE

A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors

(2011) Darin A. Wick et al.   VACCINE

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

(2011) Troy J. Kemp et al.   VACCINE

A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection

(2011) Alberto Monroy-Garcia et al.   Virology Journal

Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types

(2010) Ting Zhang et al.   VACCINE

HPV - immune response to infection and vaccination

(2010) Margaret Stanley   Infectious Agents and Cancer

Human Papillomavirus Type 16 (HPV-16) Virus-Like Particle L1-Specific CD8+ Cytotoxic T Lymphocytes (CTLs) Are Equally Effective as E7-Specific CD8+ CTLs in Killing Autologous HPV-16-Positive Tumor Cells in Cervical Cancer Patients: Implications for L1 Dendritic Cell-Based Therapeutic Vaccines

(2009) S. Bellone et al.   JOURNAL OF VIROLOGY

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

(2009) J Paavonen et al.   LANCET

Persistent Antibodies to HPV Virus-Like Particles Following Natural Infection Are Protective Against Subsequent Cervicovaginal Infection with Related and Unrelated HPV

(2009) Zainab A. Malik et al.   VIRAL IMMUNOLOGY

An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice

(2009) Georgina De la Rosa et al.   Virology Journal

Neutralizing Antibodies against Human Papillomavirus Types 16, 18, 31, 52, and 58 in Serum Samples from Women in Japan with Low-Grade Cervical Intraepithelial Neoplasia

(2008) H. Ochi et al.   Clinical and Vaccine Immunology

A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: Importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention

(2008) David Jenkins   GYNECOLOGIC ONCOLOGY

Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice

(2008) T. Bian et al.   MOLECULAR CANCER THERAPEUTICS

HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

(2008) Elmar A. Joura et al.   VACCINE